Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Apellis Pharmaceuticals Inc Market Cap
Based on ratings from 3 stock analysts, the Apellis Pharmaceuticals Inc stock price is expected to increase by 149.91% in 12 months. This is calculated by using the average 12-month stock price forecast for Apellis Pharmaceuticals Inc. The lowest target is $35 and the highest is $95. Please note analyst price targets are not guaranteed and could be missed completely.
APLS is a stock in Healthcare which has been forecasted to be worth $68.75 as an average. On the higher end, the forecast price is $95 USD by from and on the lower end APLS is forecasted to be $35 by from JP Morgan.
These are the latest 20 analyst ratings of APLS.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Derek Archila Wells Fargo | Equal-Weight | $43 | Maintains | Sep 24, 2024 |
| Colleen Kusy Baird | Outperform | $92 | Maintains | Sep 23, 2024 |
| Graig Suvannavejh Mizuho | Neutral | $39 | Maintains | Sep 20, 2024 |
| Joseph Stringer Needham | Buy | $85 | Reiterates | Sep 20, 2024 |
| Anupam Rama JP Morgan | Overweight | $57 | Maintains | Sep 13, 2024 |
| Anupam Rama JP Morgan | Overweight | $64 | Maintains | Aug 13, 2024 |
| Colleen Kusy Baird | Outperform | $96 | Maintains | Aug 9, 2024 |
| Joseph Stringer Needham | Buy | $85 | Reiterates | Aug 9, 2024 |
| Laura Chico Wedbush | Neutral | $41 | Maintains | Aug 9, 2024 |
| Eliana Merle UBS | Buy | $83 | Maintains | Aug 9, 2024 |
| Salveen Richter Goldman Sachs | Buy | $74 | Maintains | Aug 9, 2024 |
| Salveen Richter Goldman Sachs | Buy | $66 | Maintains | Aug 2, 2024 |
| Joseph Stringer Needham | Buy | $85 | Reiterates | Aug 2, 2024 |
| Douglas Tsao HC Wainwright & Co. | Buy | $83 | Maintains | Aug 2, 2024 |
| Akash Tewari Jefferies | Buy | $80 | Maintains | Jul 31, 2024 |
| Colleen Kusy Baird | Outperform | $86 | Maintains | Jul 26, 2024 |
| Colleen Kusy Baird | Outperform | $100 | Maintains | Jul 23, 2024 |
| Salveen Richter Goldman Sachs | Buy | $77 | Maintains | Jul 17, 2024 |
| Colleen Kusy Baird | Outperform | $100 | Maintains | Jun 28, 2024 |
| Biren Amin Piper Sandler | Neutral | $46 | Initiates | May 31, 2024 |
When did it IPO
2017
Staff Count
702
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Cedric Francois M.D., Ph.D.
Market Cap
$3.42B
In 2023, APLS generated $396.6M in revenue, which was a increase of 425.83% from the previous year. This can be seen as a signal that APLS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 03 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Kuehn Law is investigating potential fiduciary duty breaches by officers and directors of Apellis Pharmaceuticals (NASDAQ: APLS), which may impact shareholder interests.
Why It Matters - The investigation into Apellis Pharmaceuticals' leadership may indicate potential legal risks, impacting stock performance and investor confidence.
Tue, 01 Oct 2024
Sentiment - NEGATIVE
Source - Seeking Alpha
Summary - Apellis faces a negative CHMP opinion for pegcetacoplan in Europe but has growth potential in the U.S. with SYFOVRE and a strong cash position, supporting its promising pipeline.
Why It Matters - Apellis' U.S. growth potential and strong pipeline offset the negative European news, highlighting resilience and future profitability, key factors for investor confidence.
Wed, 25 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Apellis Pharmaceuticals will host a fireside chat at UBS Virtual Ophthalmology Day on October 2, 2024, at 8:30 a.m. ET.
Why It Matters - Apellis Pharmaceuticals' participation in the UBS Virtual Ophthalmology Day could indicate upcoming updates or insights on their pipeline, influencing stock performance and investor sentiment.
Mon, 23 Sep 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - APLS stock declines after the CHMP reaffirms its negative opinion from June 2024 regarding the regulatory filing for pegcetacoplan to treat GA in the EU.
Why It Matters - The CHMP's confirmation of a negative opinion on APLS's treatment impacts its stock by signaling regulatory hurdles, potentially limiting market opportunities and revenue growth.
Fri, 20 Sep 2024
Sentiment - NEGATIVE
Source - Investors Business Daily
Summary - European regulators rejected Apellis Pharmaceuticals' eye drug, Syfovre, causing the company's stock to drop to a month-low.
Why It Matters - Regulatory rejection of Syfovre impacts Apellis' revenue prospects, causing stock decline. This raises concerns about the company's growth potential and market confidence.
Fri, 20 Sep 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Apellis Pharmaceuticals' marketing application for intravitreal pegcetacoplan to treat geographic atrophy was negatively reviewed by the EMA's CHMP, confirming a June 2024 decision.
Why It Matters - The negative opinion from the EMA on Apellis Pharmaceuticals' drug application may lead to decreased stock performance, investor sentiment, and future revenue projections for the company.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
